Chest
Clinical Investigations ASTHMAEffects of Aerosolized Adenosine 5′-Triphosphate vs Adenosine 5′-Monophosphate on Dyspnea and Airway Caliber in Healthy Nonsmokers and Patients With Asthma
Section snippets
Patients
Healthy nonsmokers (41 ± 3 years old [± SEM], n = 10) and patients with intermittent asthma (Global Initiative for Asthma guidelines) [39 ± 3 years old, n = 10] were studied (Table 1). Healthy nonsmokers had a normal chest examination, normal lung function without reversibility, and no history of any respiratory disorder. Asthmatic patients were clinically stable and free from respiratory tract infection or use of steroids during 4 weeks preceding the study. They were subjected to methacholine
Airway Responsiveness to AMP and ATP
None of the healthy nonsmokers responded to either ATP or AMP. All patients with asthma responded to ATP, whereas 90% of them responded to AMP, ie, showing a ≥ 20% fall in FEV1 up to the maximal concentrations administered. The geometric mean PD20 ATP was 48.7 μmol/mL (26.9 mg/mL) and PD20 AMP was 113.5 μmol/mL (39.6 mg/mL) in responsive subjects (p < 0.05) [Fig 1].
ATP-induced bronchoconstriction expressed as a percentage of the baseline FEV1 (ΔFEV1) was greater than that caused by AMP
Discussion
The present data show that ATP is a more potent bronchoconstrictor and has greater effect on dyspnea and other symptoms than AMP in asthmatic patients. Furthermore, there was a significant relationship between acute changes in airway caliber and Borg score with both ATP and AMP challenges.
All patients with asthma, who were not current smokers, responded to ATP, and 90% of them were AMP responsive. Also, ATP was 2.3-fold more potent than AMP in asthmatic patients as a bronchoconstrictor. The
References (14)
Bronchoprovocation testing
Clin Chest Med
(2001)- et al.
The role of endogenous and exogenous AMP in asthma and chronic obstructive pulmonary disease
J Allergy Clin Immunol
(2004) - et al.
Standardization of bronchial inhalation challenge procedures
J Allergy Clin Immunol
(1975) - et al.
Adenosine 5′-triphosphate axis in obstructive airway diseases
Am J Ther
(2002) - et al.
ATP modulates anti-IgE-induced release of histamine from human lung mast cells
Am J Respir Cell Mol Biol
(1999) - et al.
ATP causes neurogenic bronchoconstriction in the dog
Drug Dev Res
(1998) - et al.
Lung mechanics during induced bronchoconstriction
J Appl Physiol
(1996)
Cited by (79)
Potential applications of P2X3 receptor antagonists in the treatment of refractory cough
2023, Respiratory MedicineThe discovery and development of gefapixant
2021, Autonomic Neuroscience: Basic and ClinicalCitation Excerpt :In addition, it had been demonstrated using inhalation challenge studies that ATP can produce urge to cough as well as objectively measured increases in cough frequency and with a potency greater than that associated with similar effects of adenosine, a breakdown product of ATP that has also demonstrated the propensity to activate respiratory sensory nerves. Similar findings were made also in regard to bronchospastic responses to the same provocation agents in these studies (Basoglu et al., 2005). This protussive feature of ATP was activated more sensitively in patients with chronic airways diseases (e.g., asthma), the inference being that ATP may trigger or facilitate this cough sensitivity.
Extracellular adenosine 5′-triphosphate in pulmonary disorders
2021, Biochemical PharmacologyCitation Excerpt :My kids were very impressed by his famous unusually bushy eyebrows, of which he was very proud of. Geoff’s co-authorship of our last paper together published last year, which deals with a novel P2X3R antagonist [1–143[] that is being developed as a drug candidate for the treatment of COPD and chronic cough [21], is a testament to his commitment not only to basic scientific research but also to applied research that leads to novel drug-development and therapeutic approaches that benefit patients who suffer from different disorders. Geoff’s departure is a major loss of the scientific community at large and ATP’s research in particular.
ATP cough challenge
2019, Pulmonary Pharmacology and TherapeuticsA review on the pathophysiology of asthma remission
2019, Pharmacology and TherapeuticsCough and airway disease: The role of ion channels
2017, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :P2X3 receptors are rapidly desensitised, the channel opens milliseconds following activation, and deactivates within tens of milliseconds [38]. P2X3 receptors are widely expressed on small to medium diameter sensory nerves and when activated can lead to depolarisation of airway sensory nerves and cough [39-41]. A number of ion channels are associated with the pathophysiology and symptomatology of a number of respiratory diseases including asthma, COPD and IPF [42-44] (Fig. 1).
This study was supported by Duska Scientific Co., Bala Cynwyd, PA.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).